Literature DB >> 15718509

Alpha1-antichymotrypsin gene (SERPINA3) A/T polymorphism as a risk factor for aneurysmal subarachnoid hemorrhage.

Agnieszka Slowik1, Anna Borratynska, Wojciech Turaj, Joanna Pera, Tomasz Dziedzic, Denise A Figlewicz, Marek Betlej, Tadeusz Krzyszkowski, Ryszard Czepko, Andrzej Szczudlik.   

Abstract

BACKGROUND AND
PURPOSE: The member 3 of clade A of serine proteinase inhibitors (SERPINA3), known previously as the alpha1-antichymotrypsin, is an acute phase protein, the levels of which increase in acute and chronic inflammation. The A/T polymorphism of the SERPINA3 gene influences expression of SERPINA3 protein. SERPINA3 can be related to aneurysmal subarachnoid hemorrhage (SAH) by influencing inflammation or by regulating cathepsin G activity. We studied the significance of SERPINA3 A/T polymorphism in patients with aneurysmal SAH compared with healthy controls.
METHODS: A total of 180 patients with aneurysmal SAH and 263 healthy controls were genotyped for the SERPINA3 A/T polymorphism. Aneurysmal SAH was diagnosed by cranial computed tomography or lumbar puncture and digital subtraction angiography. SERPINA3 polymorphism was detected by polymerase chain reaction amplification and restriction enzyme digestion.
RESULTS: The SERPINA3 genotype distribution in patients with aneurysmal SAH (AA-29 16.1%; AT-108 60.0%; TT-43 23.9%) differed significantly from controls (AA-70 26.6%; AT-123 46.8%; TT-70 26.6%; P=0.009). A logistic regression model showed that the presence of genotype with T allele (AT+TT; odds ratio [OR], 2.01; 95% CI, 1.19 to 3.38; P=0.009) or AA genotype (OR, 0.49; 95% CI, 0.30 to 0.84; P=0.009) of the SERPINA3 influences the risk for aneurysmal SAH independently from smoking, excessive alcohol consumption, and hypertension.
CONCLUSIONS: The A/T polymorphism of SERPINA3 gene is associated with the risk factor for aneurysmal SAH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15718509     DOI: 10.1161/01.STR.0000157598.02014.37

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  7 in total

1.  SERPINA3 Silencing Inhibits the Migration, Invasion, and Liver Metastasis of Colon Cancer Cells.

Authors:  Long-Lei Cao; Xu-Feng Pei; Xu Qiao; Jie Yu; Hui Ye; Chang-Lei Xi; Pei-Yun Wang; Zhi-Lin Gong
Journal:  Dig Dis Sci       Date:  2018-05-31       Impact factor: 3.199

Review 2.  The genetics of intracranial aneurysms.

Authors:  Boris Krischek; Ituro Inoue
Journal:  J Hum Genet       Date:  2006-05-31       Impact factor: 3.172

3.  Expression of the serine protease inhibitor serpinA3 in human colorectal adenocarcinomas.

Authors:  Jan Dimberg; Karin Ström; Sture Löfgren; Niklas Zar; Anders Hugander; Andreas Matussek
Journal:  Oncol Lett       Date:  2011-03-21       Impact factor: 2.967

4.  Genetic susceptibility to cerebrovascular disease: A systematic review.

Authors:  Christoph J Griessenauer; Sean Farrell; Atom Sarkar; Ramin Zand; Vida Abedi; Neil Holland; Andrew Michael; Christopher L Cummings; Raghu Metpally; David J Carey; Oded Goren; Neil Martin; Philipp Hendrix; Clemens M Schirmer
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-05       Impact factor: 6.200

5.  Phytochemical‑rich herbal formula ATG‑125 protects against sucrose‑induced gastrocnemius muscle atrophy by rescuing Akt signaling and improving mitochondrial dysfunction in young adult mice.

Authors:  Ching-Chuan Yeh; Hsuan-Miao Liu; Ming-Chung Lee; Yann-Lii Leu; Wei-Han Chiang; Hen-Hong Chang; Tzung-Yan Lee
Journal:  Mol Med Rep       Date:  2021-12-16       Impact factor: 2.952

Review 6.  Genetic risk factors for intracranial aneurysms: a meta-analysis in more than 116,000 individuals.

Authors:  Varinder S Alg; Reecha Sofat; Henry Houlden; David J Werring
Journal:  Neurology       Date:  2013-06-04       Impact factor: 9.910

7.  The genetics of primary haemorrhagic stroke, subarachnoid haemorrhage and ruptured intracranial aneurysms in adults.

Authors:  George Peck; Liam Smeeth; John Whittaker; Juan Pablo Casas; Aroon Hingorani; Pankaj Sharma
Journal:  PLoS One       Date:  2008-11-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.